NAC has a longer clinical track record
In 2025, the FDA expanded SKYTROFA approval to include adult growth hormone deficiency, further strengthening the commercial success of the platform
Hims & Hers said Wednesday that it will begin offering GLP-1 microdosing treatments, doubling down on selling copycat versions of the blockbuster weight-loss drugs made by Novo Nordisk
Four inter-run calibrators per chip were used as correction factors
Simply having an ingredient on the supplement facts panel doesnt ensure that youre getting enough of the ingredient to cause the desired effect
Amira Guirguis, pharmacy professor and chair of the Science and Research Committee of the Royal Pharmaceutical Society, agrees: I think weight loss has always been the aim of so many people, and [now] its about access to medicine. While the pharmaceutical giants behind Wegovy (semaglutide